A Phase 2 Randomized Study of YONSA (Abiraterone Acetate), Enzalutamide or Apalutamide as First Line Therapy in Veterans With Castrate-sensitive Prostate Cancer
Latest Information Update: 24 Jun 2022
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
Most Recent Events
- 24 Jun 2022 New trial record